Table 1.
Subject | Sex | Age | Disease | Stage | Prescription dose [Gy] | Number of Fx | Karnofsky performance status |
---|---|---|---|---|---|---|---|
1 | F | 30 | MPNST | IV | 50 | 5 | 90 |
2 | M | 72 | NSCLC | IIIB | 70 | 35 | 80 |
3 | M | 47 | Lymphoma | III | 36 | 20 | 90 |
4 | F | 47 | Lymphoma | I | 36 | 20 | 80 |
5 | M | 78 | SCLC | IV | 61.2 | 34 | 90 |
6 | F | 38 | SCLC | IV | 61.2 | 34 | 90 |
7 | F | 69 | NSCLC | IIIA | 70 | 35 | 80 |
8 | M | 69 | NSCLC | I | 70 | 35 | 90 |
9 | F | 63 | NSCLC | IV | 60 | 30 | 80 |
10 | M | 58 | NSCLC | IIIB | 65 | 35 | 100 |
11 | F | 68 | NSCLC | IIIA | 64 | 32 | 90 |
12 | M | 55 | NSCLC | IV | 66 | 33 | 80 |